Icosavax reports immunogenicity data on VLP vaccine IVX-121 for RSV

Icosavax provided a 12-month immunogenicity update from its Phase 1b extension trial of IVX-121 against Respiratory Syncytial Virus RSV in older adults. These data demonstrate substantial durability of neutralizing antibody NAb response against RSV at twelve months after a single administration of IVX-121. The company also reported initial evidence for revaccination potential with its VLP-based vaccines, including robust immune responses against RSV-A in Phase 1b extension trial participants who received 75 microgram unadjuvanted IVX-121 at one year after their first dose. “We continue to believe that there is a need for long-lasting, well-tolerated vaccines, particularly in combinations. These 12-month immunogenicity data from our Phase 1b extension trial of IVX-121 provide additional clinical evidence of a potentially differentiated durability profile for our VLP-based technology, as well as initial data supporting the potential for revaccination to boost immune responses in the second year,” said Adam Simpson, Chief Executive Officer of Icosavax…Icosavax is pleased to report that dosing has been completed in its Phase 2 trial of IVX-A12, and the company now expects to announce topline interim data by the end of 2023 versus the prior guidance of 1Q 2024.